


301 Rec'd PCT/PTO 17 DEC 1999



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		001560-377
INTERNATIONAL APPLICATION NO. PCT/JP99/02045	INTERNATIONAL FILING DATE April 16, 1999	PRIORITY DATE CLAIMED April 17, 1998
TITLE OF INVENTION GENE ENCODING A PROTEIN HAVING AURONE SYNTHESIS ACTIVITY		
APPLICANT(S) FOR DO/EO/US Keiko SAKAKIBARA, Yuko FUKUI, Yoshikazu TANAKA, Takaaki KUSUMI, Masako MIZUTANI, Toru NAKAYAMA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) </p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 16. below concern other document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>		

420 Rec'd PCT/PTO 17 DEC 1999

U.S. APPLICATION NO. (Unknown, See 37 C.F.R. 1.10)		INTERNATIONAL APPLICATION NO. PCT/JP 99/02045	ATTORNEY'S DOCKET NUMBER 001560-377
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$840.00 (970) International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 (958) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 (958) Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 (960) International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 (962)			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 840.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).		20 <input type="checkbox"/> 30 <input type="checkbox"/>	\$
Claims	Number Filed	Number Extra	Rate
Total Claims	17 -20 =	0	X\$18.00 (966) \$ 0.00
Independent Claims	1 - 3 =	0	X\$78.00 (964) \$ 0.00
Multiple dependent claim(s) (if applicable)		+\$260.00 (968) \$ 0.00	
TOTAL OF ABOVE CALCULATIONS =		\$ 840.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$	
SUBTOTAL =		\$ 840.00	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).		20 <input type="checkbox"/> 30 <input type="checkbox"/> +	\$
TOTAL NATIONAL FEE =		\$ 840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31), per property +		\$ 40.00	
TOTAL FEES ENCLOSED =		\$ 880.00	
		Amount to be: refunded	\$
		charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 880.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 02-4800 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:			
Ronald L. Grudziecki BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404		 SIGNATURE <u>Donna M. Meuth</u> NAME <u>36-607</u> REGISTRATION NUMBER	

09/446089

420 Rec'd PCT/PTO 17 DEC 1999

Patent

Attorney's Docket No. 001560-377

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
KEIKO SAKAKIBARA et al.) Group Art Unit: Unassigned
Application No.: Unassigned) Examiner: Unassigned
Corresponding to PCT/JP99/02045)
Filed: December 17, 1999)
For: GENE ENCODING A PROTEIN)
HAVING AURONE SYNTHESIS)
ACTIVITY)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-cited Application on the merits, please amend the application as follows:

IN THE CLAIMS:

In claim 3, line 1, please delete "or 2".

In claim 4, line 1, please delete "or 2".

In claim 5, line 1, please delete "or 2".

In claim 6, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 10, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 13, line 5, please delete "or claim 11".

Patent
Attorney's Docket No. 001560-37

In claim 14, line 2, please delete "or claim 11".

In claim 15, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 16, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

REMARKS

Entry of the foregoing and early and favorable consideration of the subject application is respectfully requested.

By the present amendment, claims 3-6, 10, and 13-16 have been amended to remove multiple dependency. No new matter has been added.

In the event that there are any questions concerning the present amendment, or the application in general, the Examiner is respectfully urged to telephone the undersigned attorney so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Donna M. Meuth
Donna M. Meuth
Registration No. 36,697

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: December 17, 1999

- 1
420 Rec'd PCT/PTO 17 DEC 1999

SPECIFICATION

GENE ENCODING A PROTEIN HAVING AURONE SYNTHESIS ACTIVITY

5 Field of the Invention

The present invention relates to genes encoding proteins having activity that synthesizes aurones by using chalcones as substrates, and its utilization. More specifically, the present invention relates to genes encoding polyphenoloxidases having activity that synthesizes aurones by using chalcones as substrates, and its utilization. More specifically, the present invention, for example, relates to genes encoding proteins derived from snapdragons having activity that synthesizes aurones by using chalcones as substrates.

Background Art

20 The flower colors of orange, red, violet and blue primarily are provided by flavonoids referred to as anthocyanins. Although yellow is mainly provided by compounds other than flavonoids, such as carotenoids, betalains, etc., the yellow color of some plants is provided by flavonoids. For example, compounds classified as aurones are known to be present in the 25 petals of some varieties of snapdragon, limonium, morning glory, dahlia, strawflower, Jerusalem artichoke and cosmos (Saito: BIO HORTI 1, 49-57, 1990).

Known examples of aurones include 4',6-dihydroxyaurone, 4,4',6-trihydroxyaurone, aureusidin, 30 sulfretin and bracteatin, with aureusidin and bracteatin being contained in snapdragon, aureusidin contained in limonium, aureusidin contained in morning glory, sulfretin contained in dahlia, bracteatin contained in strawflower, and sulfretin contained in Jerusalem artichoke.

35 In addition, aurones are known to be contained in the plant of the family Compositae including the genera

5 Coreopsis, Helianthus, Tithonia, Zinnia and Viguiera; the family Ericaceae including the genus Vaccinium; the family Cyperaceae including the genus Cyperus; the family Leguminosae including the genera, Acacia, Pterocarpus and Soja; and the family Rubiaceae including the genus Mussaenda (The Flavonoids, edited by J.B. Harbone, 1988, Chapman & Hall, 340-342).

10 The synthesis pathway of anthocyanins has been extensively researched, and with respect to the biosynthesis of aurones, it has been suggested based on its structure that 4',6-dihydroxyaurone is synthesized from 2',4,4'-trihydroxychalcone, and it has been proposed that peroxidase is involved in that reaction (Rathmel and Bendall, Biochem. J. 127, 125-132, 1972). However, there 15 are no examples of definitively measuring the biosynthesis reaction of aurones using petal extracts and so forth of plants, and there are no reports that clarify the manner in which the reaction occurs in plant petals. In addition, there are also no reports of purifying 20 enzymes involved in aurone synthesis.

Disclosure of the Invention

25 Therefore, the inventors of the present invention have attempted to clarify the biosynthesis mechanism of aurones to provide a means for controlling the color of plants, and particularly their flowers.

30 The inventors of the present invention established an assay method for measuring the reaction by which aurones are synthesized from chalcones using a crude extract of snapdragon petals containing aurones. The aurones produced at this time are not 4',6-dihydroxyaurone considered in the prior art, but rather aureusidin, and this reaction that can now be measured has not been previously known. In addition, an enzyme 35 (aureusidin synthase) that synthesizes aurones (aureusidin) by using chalcones as substrates from the petals of snapdragons was purified by electrophoresis to

a single band, by using the assay method. The biochemical properties of this enzyme were identified using this pure standard. In addition, the partial amino acid sequences of this enzyme were also determined. A 5 gene for this aurone synthase, which synthesizes aurones by using chalcones as substrates, was obtained from a cDNA library prepared from the petal of snapdragon, based on the partial amino acid sequences as described above.

10 Note that known examples of chalcones include, but not restricted to tetrahydroxychalcone, pentahydroxychalcone, butein and 2',4,4'-trihydroxychalcone.

15 On the other hand, the resulting gene has homology in the copper binding region, which is the active center of polyphenol oxidase. Therefore, it was confirmed whether tyrosinase, which is known as a kind of polyphenol oxidases, has activity to synthesize aurones from chalcones or not, and as a result, tyrosinase was also clearly shown to have activity to synthesize 20 aurones.

25 Thus, the present invention provides genes encoding proteins having activity to synthesize aurones by using chalcones as substrates. Moreover, it provides genes encoding polyphenol oxidase having activity to synthesize aurones by using chalcones as substrates. Moreover, it provides a gene encoding a protein having activity to synthesize aurones by using chalcones as substrates, and having the amino acid sequence shown in SEQ ID NO. 2. The present invention also provides a vector containing 30 the above-mentioned gene.

Moreover, the present invention provides a host transformed by the above-mentioned vector. This host may be a microorganism, plant cells or animal cells, or it may be a plant.

35 The present invention also provides a process for production of an aurone synthase such as aureusidin synthase, characterized by culturing the above-mentioned

5 cells or cultivating the above-mentioned plant. The formed enzyme can be recovered, or be made to function to regulate the color tone in a plant. In this case, aurones are synthesized by enzyme formed in the plant, and these aurones then regulate the color of the plant such as its petals.

10 Thus, the present invention also provides a method for regulating the flower color of plants characterized by introducing a gene for an enzyme such as aureusidin synthase having activity to synthesize aurones by using chalcones as substrates into a plant or plant cells to express above-mentioned gene, and by synthesizing aurones in a plant by the enzyme formed. The present invention 15 also provides a plant in which flower color is regulated in this manner.

20 The present invention also provides a method of synthesizing aurones characterized by allowing the above-mentioned enzyme protein to act on chalcones serving as the substrate pigment.

25 The present invention also provides an enzyme protein encoded by the above-mentioned gene.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the structural formulas of aurones and 25 chalcones.

Fig. 2 shows the biosynthesis pathway of aurones.

Fig. 3 shows the results of Northern analysis in each organ of yellow snapdragon using SYP8-17.

30 Fig. 4 shows the results of Northern analysis at each stage of development of the petals of yellow snapdragon using SYP8-17.

Petal stage 1: Bud petal length up to 1 cm

Petal stage 2: Bud petal length 1 to 1.5 cm

Petal stage 3: Bud petal length 1.5 to 2.0 cm

35 Petal stage 4: Bud petal length 2.0 to 2.5 cm

Petal stage 5: Bud petal length 2.5 to 3.0 cm

Petal stage 6: Blossomed petal 3.0 cm or more

Fig. 5 shows the results of Northern analysis in yellow, pink and white snapdragon petals using SYP8-17.

5 Fig. 6 is a graph showing an inhibition mode of aurone synthase activity by adding antibody against aurone synthase SYP-8 (anti-SYP-8) and other reference antibodies (anti-band A and anti- β -galactosidase).

Fig. 7 shows SYP8 protein remaining in supernatant after addition of anti-SYP8-IgG-Sepharose 4B.

10 EMBODIMENT FOR CARRYING OUT THE INVENTION

To begin with, aureusidin synthase is purified by various chromatography methods from the petals of yellow snapdragon. Next, partial amino acid sequences of aureusidin synthase are analyzed in accordance with a 15 conventional method to prepare synthetic oligonucleotides encoding these amino acid sequences.

20 On the other hand, Poly A+RNA is prepared from the same snapdragon petals, and cDNA library is prepared in accordance with a conventional method.

25 PCR is carried out using the above-mentioned synthetic nucleotides using cDNA of yellow snapdragon petals as a template to acquire a DNA fragment specific to aureusidin synthase. This DNA fragment is subcloned in a vector to prepare a plasmid.

30 The above-mentioned cDNA library is screened using an inserted DNA contained in the above-mentioned plasmid to obtain a clone. The plasmid derived from this clone is then isolated followed by determination of the nucleotide sequence.

35 The protein having the enzyme activity has a region essential for an enzyme activity, and a region not essential for enzyme activity. It is known that enzyme activity is maintained even if the non-essential region is modified by removal (deletion) or addition of one or more amino acids and/or substitution by other amino acids. Thus, the present invention includes not only a protein having the amino acid sequence shown in SEQ ID

NO. 2, but also proteins having an amino acid sequence modified by removal, deletion or addition of one or more amino acids and/or one or more substitutions by other amino acids in the amino acid sequence shown in SEQ ID 5 NO. 2 while maintaining the activity to synthesize aurones by using chalcones as substrates, as well as genes encoding the proteins.

Moreover, cases are known in which a protein having identical enzyme activity may have a different amino acid 10 sequence due to an allelic variation. Moreover, it is also known that enzymes having identical or equivalent enzyme activity are distributed over numerous species, and that these enzymes have a high degree of homology of their amino acid sequences. Genes encoding these 15 proteins can be selected by hybridization with a gene of the present invention. Thus, the present invention also includes a gene that hybridizes with nucleic acid having the nucleotide sequence shown in SEQ ID NO. 1 under a stringent condition and that encoding a protein having 20 the activity to synthesize aurones by using chalcones as substrates, and a protein encoded by the gene.

The gene that hybridizes with nucleic acid having the nucleotide sequence described in SEQ ID NO. 1 and that encoding a protein having enzyme activity to 25 synthesize aurones by using chalcones as substrates may be an artificially modified form or naturally-occurring form of a gene that encodes the amino acid sequence described in SEQ ID NO. 2. Examples of naturally-occurring genes include cDNA or genomic DNA obtained from 30 plants having aurone synthase such as snapdragon, limonium, morning glory, dahlia, strawflower and Jerusalem artichoke. The stringency for hybridization is, for example, 5 x SSC at 50°C, preferably 2 x SSC at 50°C, and more preferably 0.2 x SSC at 50°C.

35 It is well known that there are many cases in which protein, having an amino acid sequence with a high degree of identity relative to a native amino acid

sequence of a protein having enzyme activity, has enzyme activity that is similar to that of a native protein. Thus, the present invention also includes proteins having activity to synthesize aurones by using chalcones as substrates and having an amino acid sequence having amino acid sequence identity of 55% or more, preferably 60% or more, preferably 70% or more, more preferably 80% or more and particularly preferably 90% or more relative to the amino acid sequence shown in Sequence ID No. 2, and a gene encoding that protein.

It is also known that enzymes having equivalent enzyme activity may have common epitopes in many cases. Thus, the present invention also includes the above-mentioned various proteins having aurone synthesis activity, and particularly proteins having activity that synthesizes aurones by using chalcones as substrates, which also specifically bind with an antibody against the protein having the amino acid sequence shown in SEQ ID NO. 2, and a gene encoding that protein.

In the present invention, a gene that encodes protein having the amino acid sequence shown in SEQ ID NO. 2 can be obtained from snapdragon as cDNA or genomic DNA. A method for cDNA cloning is specifically described in Examples 8 through 10. In order to obtain a genomic DNA, a genomic DNA library is prepared from snapdragon in accordance with a conventional method, and this is then screened in accordance with a conventional method by cDNA or its fragment.

In the present invention, a gene that encodes a protein having a modified amino acid sequence relative to the amino acid sequence in SEQ ID NO. 2 can be prepared by modifying the nucleotide sequence of DNA such as cDNA that encodes protein having the amino acid sequence shown in SEQ ID NO. 2 in accordance with a conventional method to manipulate the gene by site-directed mutagenesis, PCR and so forth.

Naturally-occurring genes, that hybridize with

nucleic acid having the nucleotide sequence described in SEQ ID NO. 1 and that encodes an enzyme having activity to synthesize aurones by using chalcones as substrates, are obtained by preparing a cDNA library or genomic DNA library from a plant which has ability to produce a protein having aurone synthase activity in accordance with a conventional method, and then screening the library by using, for example, cDNA or its fragment having the nucleotide sequence shown in SEQ ID NO. 1 as a probe. The above-mentioned conditions can be used for the hybridization at this time.

In addition, the aurone synthase obtained from snapdragon is a kind of polyphenol oxidase, therefore the inventors of the present invention, considering that other polyphenol oxidases also have activity to synthesize aurones from chalcones, examined whether an enzyme sold commercially as tyrosinase, a polyphenol oxidase derived from Neurospora, has aurone synthesis activity or not. As a result, the tyrosinase was determined to have aurone synthesis activity. Consequently, enzymes having polyphenol oxidase activity clearly have activity to synthesize aurones by using chalcones as substrates.

Although the physiological role of enzymes having polyphenol oxidase activity is not yet clear, they are primarily classified into three types which are catechol oxidase (enzyme no. 1.10.3.1), laccase (enzyme no. 1.10.3.2.) and tyrosinase (enzyme no. 1.14.18.1), and are classified with different enzyme numbers according their substrate specificity. They are copper enzymes in which copper is present in the enzyme reaction center, and high dimensional structures of proteins, etc. are thought to be a cause of substrate specificity.

In this manner, since a conserved region corresponding to the copper-binding region is present in polyphenol oxidase, polyphenol oxidase gene can be obtained according to an established method such as PCR

with a primer based on the amino acid sequence of this region (Plant Physiol., Vol. 107, pp. 1083-1089, 1995; Plant Physiol., Vol 109, pp. 525-531, 1995), and a gene encoding a protein having activity to synthesize aurones 5 can be obtained from the gene obtained as described above.

The present invention also provides a process for production of the above-mentioned proteins having activity to synthesize aurones by using chalcones as 10 substrates. This method is characterized by introducing a vector containing a DNA encoding the above-mentioned protein into a host, culturing or growing said host, and collecting the above-mentioned protein as desired. The host may be host cells or plants or other organisms. 15 Examples of host cells include prokaryotic cells and particularly bacterial cells such as those of Escherichia coli, and the genus Bacillus including the species Bacillus subtilis and Bacillus brevis, and lower eucaryotes, including fungi such as yeasts like the genus 20 Saccharomyces such as the species Saccharomyces cerevisiae, or molds like the genus Aspergillus such as the species Aspergillus oryzae and Aspergillus niger.

Moreover, examples of higher eucaryotic cell hosts include insect cells such as silkworm cells, animal cells 25 such as CHO cells, and human cultured cells such as HeLa cells.

The gene described in the present invention can also be expressed in organisms such as animals and plants. A detailed description of expression in plants is provided 30 below.

A vector, and particularly an expression vector, containing DNA of the present invention contains an expression control region, and this expression control region is dependent on the host cells. For example, trc 35 promoter, tac promoter, lac promoter or T7 promoter can be used for the promoter of a bacterial expression vectors. Examples of promoters of a yeast expression

vector that can be used include promoters of glycolytic enzyme genes such as glycerolaldehyde-3-phosphate dehydrogenase promoter and galactokinase promoter. In addition, virus promoters can be used as a promoter of animal cell expression vectors.

Conventional means used to isolate and purify proteins, such as liquid chromatography and affinity chromatography, can be used to recover a protein having an activity to synthesize aurones from a culture by using chalcones as substrates. Affinity chromatography can be performed using the specific binding with antibody, for example antiserum or monoclonal antibody, against protein having aurone synthase activity of the present invention.

Antiserum (polyclonal antibody) to protein having aurone synthase activity described in the present invention can be produced by immunizing an animal such as a rabbit with protein described in the present invention, such as the protein obtained in Example 4, together with adjuvant, and obtaining serum from the animal. Monoclonal antibody can be produced by immunizing an animal such as a mouse against, for example, a protein described in the present invention in accordance with a conventional method, and fusing the B lymphocytes, such as spleen cells, obtained from a mouse, with mouse myeloma cells to obtain a hybridoma, followed by culturing that hybridoma.

Based on the current level of technology, if the cDNA can be put under the control of a constitutive or inducible promoter, and introduced into a plant such as petunia, rose, carnation, chrysanthemum, torenia, verbena, gerbera, tobacco, strawberry, Jerusalem artichoke, gentian, gladiolus or tulip, using Agrobacterium, a particle gun or electroporation, the aurone synthase gene can be expressed in a petal and so forth.

It is predicted that aurones are synthesized in petals where aurone synthase is expressed, which cause

the yellow color of the petals. Plants obtained in this manner are able to provide new colors of flowers that do not exist for conventional varieties. In addition, some of plant species having yellow color contain carotenoids (chrysanthemums and roses) or betalain (cactus), but the tone of these yellow colors are different from those by aurones. Therefore, the present invention is also useful in enlarging the spectrum of color tones of plant species already having yellow color.

Some snapdragons having yellow flowers are deficient in chalcone isomerase activity and have aurone synthase. Since chalcone isomerase acts competitively with aurone synthase, naringenin is formed from tetrahydroxychalcone in the presence of chalcone isomerase, and this ultimately becomes anthocyanin and flavone. Thus, when producing aurones by expressing aurone synthase gene in plants, it is preferable that the plant be deficient in chalcone isomerase.

In general, it is possible to artificially suppress the activity of plant genes, and there are numerous known examples of suppressing genes involved in flavonoid synthesis in particular. An antisense method and a cosuppression method are used to artificially suppress gene expression, and genes involved in flavonoid synthesis have been found to be able to be suppressed by either of these methods (van der Krol, et al., *Nature* (1988) 333, 866-869; Napoli, et al., *Plant Cell* (1990) 2, 279-289). It is also possible to suppress expression of chalcone isomerase gene in the same way.

Chalcone isomerase gene has already been obtained from plant species, such as petunia, alfalfa, snapdragon, apple, kidney bean and grape (Holton, et al., *Plant Cell* (1995) 7, 1071-1083). Comparison of the amino acid sequences of these chalcone isomerases reveals that the sequence is well conserved among species. There are many examples that genes involved in flavonoid synthesis can be easily cloned by using a corresponding gene derived

from another plant as a probe. Alternatively, cloning can also be performed by PCR using a conserved region of known genes or amino acid sequences compared with each other. Thus, chalcone isomerase gene can be easily 5 obtained from any plant species (Guttersen, Hort. Sci., Vol. 30, pp. 964-966, 1995).

In addition, similar effects can be expected by suppressing gene expression of flavanone-3-hydroxidase or dihydroflavonol-4-reductase. Since these enzyme genes 10 have also been obtained from numerous plant species (Gong, et al., Plant Mol. Biol., 35, pp. 915-927, 1997), they can be obtained from any plant species by using a method similar to the case of chalcone isomerase.

Thus, in order to breed a certain plant species 15 having yellow flowers provided by aurones, the aurone synthase gene should be expressed in the petals. Preferably, the aurone synthase gene should be expressed while suppressing the expression of chalcone isomerase gene. In this case, the promoters used to regulate 20 expression of these genes may be constitutional promoters or petal-specific promoters. More preferably, these techniques allow to obtain flowers with stable yellow color in combination with introduction of a glycosyltransferase gene that adds a sugar to the aurone. 25 These techniques are possible with the current level of technology.

Furthermore, in dahlia and snapdragon, flower color 30 is known to become brown when both anthocyanins and aurones are present. It is possible to breed brown flowers by introducing aurone synthase into a plant that produces anthocyanins in its flowers. Such flowers are also industrially important as a new color of flowers.

Examples

35 The following provides a detailed description of the invention through its examples.

Example 1. Preparation of Tetrahydroxchalcone

20 ml of 50% (v/w) potassium hydroxide were added to 4 g of naringenin and completely dissolved. After holding this solution at 100°C for 90 seconds, the solution was immediately diluted and cooled with 300 ml of ice water to stop the reaction. Next, 6 N hydrochloric acid was added to this solution in a draft chamber to lower the pH to 3 or lower and form a precipitate. The resulting yellow precipitate was filtered out of solution and dissolved in a minimum amount of ethanol, followed by the addition of 400 ml of cold water a little at a time while cooling over ice. After allowing to stand overnight, the precipitate obtained by centrifuging at 8000 rpm for 30 minutes was resuspended in water and freeze-dried. The weight of crude tetrahydroxychalcone (THC) after freeze-drying was 2.7 g.

The crude THC was dissolved in a minimum amount of methanol, and the THC was purified by reverse phase high-performance liquid chromatography. The THC was developed using the Shimakyyu YMC D-ODS-5 S-5 120A (2.0 cm x 25 cm) at a flow rate of 4.5 ml/min in an aqueous solution of 40% (v/v) acetonitrile and 0.03% (v/v) trifluoroacetic acid. THC was eluted at about 25 minutes, while naringenin was eluted at about 29 minutes. The THC fractions were collected and freeze-dried. Chromatography was repeated once under the same conditions to obtain purified THC.

Example 2. Preparation of Aureusidin

290 g of the petals of snapdragon cultivar Butterfly Yellow were crushed in liquid nitrogen and soaked overnight in 2 liters of 50% acetonitrile containing 0.1% TFA. After filtering through diatomaceous earth and concentrating the filtrate under reduced pressure, the concentrate was purified with HP-20. The yellow pigment fraction was concentrated and applied to a separation HPLC. Using water as solution A and 0.1% TFA in 50% acetonitrile as solution B, chromatography was performed

using the Shimakyuu YMC D-ODS-5 S-5 120A (2.0 cm x 25 cm) under gradient condition of 120 minutes at a linear concentration gradient from 20% B to 60% B. As a result, bracteatin-6-glucoside was eluted at 40 minutes, aureusidin-6-glucoside was eluted at 53 minutes, and tetrahydroxychalcone-4-glucoside was eluted at 100 minutes. The resulting aureusidin-6-glucoside was hydrolyzed with β -glucosidase to obtain aureusidin.

Example 3. Measurement Method of Aurone Synthase

Activity

The reaction was started by adding 5 μ l of THC, having an absorbance of 462 at 366 nm in ethanol, to 50 μ l of 1 M sodium acetate buffer (pH 5.0) and 350 μ l of crude enzyme solution diluted with water. After allowing to react for 1 hour at 30°C, and adding 100 μ l of an aqueous solution of 90% (v/v) acetonitrile containing 1% (v/v) TFA to stop the reaction, activity was measured by HPLC. The crude enzyme solution in each purification step described later in Example 4 was measured.

20 The YMC J'Sphere ODS M80 column (4.6 x 150 mm) was
used and the flow rate was set at 0.7 ml/min. Using a
0.1% aqueous solution of TFA as solvent A, and a 90%
aqueous solution of acetonitrile containing 0.1% TFA as
solvent B, a sample was injected into the column, after
25 which the ratio of A:B was held at 7:3 for first 3
minutes, and then changed to 6:4 by a linear
concentration gradient for next 10 minutes. This
concentration was maintained for 5 minutes. After
changing the ratio of A:B to 7:3 for next one minute,
30 this concentration was maintained for 5 minutes. The
substrate THC was eluted at about 20.9 minutes under
these conditions. A compound eluted at about 8.8 minutes
was detected as a reaction product. This compound was
aureusidin as described later.

35 Aureusidin was determined to be formed from THC by
this reaction.

Example 4. Purification of Aurone Synthase

1) Enzyme Purification

Enzyme purification was carried out using as a starting material 32,175 g of snapdragon buds from which white petals were peering out from between calyx and flowers that had started to be colored yellow. 2400 ml of chilled buffer A (0.01 M sodium acetate, pH 5.0) and 120 g of polyvinylpolypyrrolidone (PVPP) were added per approximately 600 g of flowers and then crushed for 1 to 1.5 minutes with a whirling blender.

Extracts from the crushed flowers were centrifuged at 8000 rpm and 4°C for 15 minutes, and ammonium sulfate was dissolved to 60% of saturation in the resulting supernatant. After stirring to dissolve, the solution was allowed to stand. The precipitate collected by centrifuging at 8000 rpm and 4°C for 15 minutes was suspended in a minimum amount of buffer A and dialyzed against buffer A. The dialysate was centrifuged at 8000 rpm and 4°C for 15 minutes, and the resulting supernatant was used as ammonium sulfate fraction concentrate. The ammonium sulfate fraction concentrate was stored frozen at -20°C until SP-Sephadex C50 chromatography.

2) SP-Sephadex C50 Chromatography

The resulting ammonium sulfate fraction concentrate was subjected to the following procedure three times. The electrical conductivity of the ammonium sulfate fraction concentrate was measured after dialysis, and the concentrate was diluted with cold deionized water as necessary until the electrical conductivity became 0.8 to 1 mS at 4°C. The ammonium sulfate fraction concentrate was applied onto an SP-Sephadex C50 column (6 cm x 25.5 cm; approx. 0.7 liters) which had been equilibrated thoroughly with buffer B (buffer A containing several μ M THC). After the application, the column was thoroughly washed with buffer B. Elution was performed in 23 ml fractions while washing the column by

5 applying a linear concentration gradient between buffer B (2.0 liters) and buffer B containing 0.6 M NaCl (2.0 liters). The active fractions (approx. 1200 ml) were collected, sterilized by filtration, and stored at 4°C until ConA Sepharose chromatography.

3) ConA Sepharose Chromatography

10 ConA Sepharose chromatography was performed in twice for fraction A (containing 374,000 U in 1100 ml) and fraction B (containing 831,000 U in 2900 ml). MnCl₂ and CaCl₂ were dissolved in the fraction A to 1 mM each and applied onto a ConA Sepharose column (2 cm x 12 cm; approx. 40 ml) which had been equilibrated with buffer C (buffer B containing 1 mM MnCl₂, 1 mM CaCl₂ and 0.5 M NaCl). After the application, the column was washed with 15 approximately 0.3 liters of buffer C. The flow-through fraction and washing fraction (300 ml) contained 50,000 U each of activity respectively before application (13% each of the original activity).

20 After washing, elution was performed in 4 ml fractions while washing the column by applying a linear concentration gradient between buffer C (250 ml) and buffer C containing 0.2 M methyl- α -D-glucoside and 0.2 M methyl- α -D-mannopyranoside (250 ml) so as to collect 25 active fractions (total 78 ml). The active fraction was thoroughly dialyzed against buffer D (5 mM potassium phosphate buffer (pH 5.0), 0.3 mM CaCl₂ and 3 to 6 μ M THC). The washing fraction was combined with the remaining fraction B, and the second round of chromatography was carried out.

30 MnCl₂ and CaCl₂ were each dissolved to 1 mM in the remaining active fraction B, and applied onto a ConA Sepharose column (3.6 cm x 12 cm; approx. 120 ml) which had been equilibrated with buffer C. After the application, the column was washed with approximately 0.3 liters of buffer C. The flow-through fraction and 35 washing fraction (300 ml) contained little activity.

After washing, elution was performed in 8 ml fractions while washing the column by applying a linear concentration gradient between buffer C (350 ml) and buffer C containing 0.2 M methyl- α -D-glucoside and 0.2 M methyl- α -D-mannopyranoside (350 ml) so as to collect active fractions (total 150 ml). After thoroughly dialyzing the active fraction against buffer D, the dialyzate was combined with the previous sample to obtain a active fraction (total 250 ml).

10 4) Gigapite Chromatography

Dialysate (250 ml) was applied onto a Gigapite column (Biochemical Industries, 2 cm x 16 cm, 50 ml open column) which had been equilibrated with buffer D. After the application of the sample, the column was washed with buffer D (250 ml). Elution was performed in 4 ml fractions while washing the column by applying a linear concentration gradient between buffer D (200 ml) and 0.5 M potassium phosphate buffer (pH 5.0) (200 ml) so as to collect active fractions (total 120 ml).

15 20 5) HiLoad 16/60 Superdex 75 pg FPLC

{3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate} (CHAPS) was dissolved to a final concentration of 0.1% in the active fraction, followed by ultrafiltration using an Amicon PM10 film to concentrate to 18 ml. The following procedure was performed 6 times on the concentrated active fraction.

25 30 A chilled HiLoad 16/60 Superdex 75 pg column was equilibrated with buffer B containing 0.07% CHAPS and 0.15 M NaCl, eluted at a flow rate of 0.5 ml/min to obtain 2 ml fractions using an FPLC system. Active fractions were collected (total 63 ml).

6) SP-Sepharose FF FPLC

35 The resulting active fraction was thoroughly dialyzed at 4°C against buffer E (buffer B containing 0.07% CHAPS). The following chromatography procedure was performed twice using an FPLC system. A chilled SP-

Sepharose FF column (1 x 16 cm) was equilibrated with buffer E. After applying the sample onto the column, buffer E was used as solution A and buffer E containing 0.7 M NaCl was used as solution B. The column was washed 5 for first 30 minutes with 95% solution A and 5% solution B, a linear concentration gradient to 55% solution A and 45% solution B was then applied for next 120 minutes, followed by elution for next 10 minutes under the same conditions. Elution was performed in 1.0 ml fractions at 10 a flow rate of 0.5 ml/min. Active fractions (total 27.8 ml) were collected and stored at 4°C after sterilizing by filtration.

7) Gigapite Column Chromatography

15 22 ml of the active fraction was further purified by Gigapite (1 x 14 cm) FPLC. 22 ml of sample was dialyzed overnight at 4°C against 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS, FPLC was performed under the following conditions, and the correlation between activity and protein band behavior 20 was observed. FPLC was performed while chilling the column and buffer using 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS and 0.3 mM CaCl₂ as solution A, and 0.5 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS as solution B.

25 After washing the column for 30 minutes with 100% solution A at a flow rate of 0.5 ml/min, a linear concentration gradient to 95% solution A and 5% solution B was applied for next 6 seconds, and then to 20% solution A and 80% solution B for next 149 minutes 54 seconds, followed by eluting under the same conditions 30 for next 155 minutes in 1.0 ml fractions.

35 Those fractions were collected that contained 40 kDa protein which demonstrated the best correlation with activity behavior based on chromatography and activity measurement results, and were used in primary structure analysis.

Example 5. Activity Measurement for Three Types
Column Chromatography and SDS-PAGE

1) Superdex 200 Smart System

Fractionation was performed with a Superdex 200
5 Smart System using 50 μ l of sample. The following
procedure was performed at 4°C using 0.01 M sodium
acetate (pH 5.0) containing 0.07% CHAPS and 0.15 M NaCl
as a solvent. Gel filtration chromatography was
performed by fractioning in 40.0 μ l aliquots at a flow
10 rate of 40.0 μ l/min. Activity measurement and SDS-PAGE
was performed for the sample. Enzyme activity was eluted
in the vicinity of a molecular weight of 43 kDa, and
among those proteins contained in the sample, the
behavior of the 40 kDa protein correlated most closely
15 with activity behavior.

2) Alkyl-Sepharose HR5/5 FPLC

250 μ l of sample was dialyzed overnight at 4°C
against 0.01 M sodium acetate (pH 5.0), and ammonium
sulfate was dissolved to a final concentration of 2 M.
Alkyl-Sepharose HR5/5 FPLC was performed at room
20 temperature. Using 0.01 M sodium acetate (pH 5.0)
containing 2 M $(\text{NH}_4)_2\text{SO}_4$ as solution A, and 0.01 M sodium
acetate (pH 5.0) as solution B, the column was washed
with 100% solution A for first 10 minutes, a linear
25 concentration gradient to 100% solution B was applied for
next 50 minutes, and elution was performed for next 5
minutes under the same condition in 0.5 ml fractions.

400 μ l of each fraction was concentrated to 40
30 μ l with Ultra-Free C3GC (molecular weight fractionated:
10,000, Millipore), and 10 μ l of the concentrate was
analyzed by SDS-PAGE and measured activity. Among the
proteins contained in the sample, the best correlation
was observed between activity behavior and the behavior
of the 40 kDa protein.

35 3) Gigapite HR5/5 FPLC

300 μ l of sample was dialyzed overnight at 4°C against 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS. Gigapite HR5/5 FPLC was performed at room temperature under the following 5 conditions.

Using 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS and 0.3 mM CaCl₂, as solution A, and 0.5 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS as solution B, the column was 10 washed with 100% solution A for first 5 minutes, and a linear concentration gradient to 80% solution A and 20% solution B was applied for next 6 seconds and then to 20% solution A and 80% solution B for next 44 minutes 54 seconds, after which 0.5 ml fractions were eluted. 15 Activity measurement and SDS-PAGE electrophoresis were then performed. Among the proteins contained in the sample, the best correlation was observed between the behavior of the 40 kDa protein and activity behavior.

As a result of conducting column chromatography 20 with the Superdex 200 Smart System, Alkyl-Sepharose FPLC and Gigapite FPLC, a close correlation was demonstrated between the behavior of the approximately 40 kDa protein band and activity behavior.

Example 6. Characteristics of Aurone Synthase
25 It was confirmed that purified aurone synthase converts both THC and pentahydroxychalcone to aureusidin. The resulting product was confirmed to be aureusidin by HPLC analysis.

The molecular weight of this enzyme was determined 30 to be 40 kDa with SDS polyaklylamide gel electrophoresis, and 43 kDa with gel electrophoresis using Superdex 200. This data revealed that aurone synthase is a monomer. Enzyme activity was inhibited by 90% or more in the presence of 1 mM monovalent copper ion, bivalent copper 35 ion, bivalent iron ion and trivalent iron ion. In addition, binding to ConA Sepharose suggested the possibility that the enzyme contains sugar. In addition,

activity increased somewhat when hydrogen peroxide was added.

A product expected to be aureusidin was formed when the enzyme reacted with THC as substrate, and its structure was determined by collecting a large amount of this product. 20 ml of 1 M sodium acetate buffer (pH 5.0) containing 10 mM hydrogen peroxide, 20 ml of enzyme solution, 58 ml of water and 10 mg (0.5 ml) of THC were mixed and held for 3.5 hours at 30°C. After reacting, the reaction mixture was adsorbed onto Sep-Pak C18 and eluted with methanol. After concentrating with an evaporator, it was purified with separation HPLC, using a YMC D-ODS-5 S-5 120A (2.5 x 25 cm) column. Elution was performed at a flow rate of 4.5 ml/min using an aqueous solution of 40% acetonitrile containing 0.03% TFA. The peak that eluted at approximately 17 minutes was collected and dried to obtain approximately 4.9 mg of product. Determination of the structure of the compound by ¹H-NMR and mass spectrometry revealed it to be aureusidin.

Example 7. Determination of Amino Acid Sequences of Aurone Synthase

Approximately 1 nmol of the resulting aurone synthase, to which SDS had been added to a final concentration of 2%, was subjected to a preparative electrophoresis (Biophoresis, Atoh) under non-reducing conditions so as to recover a polypeptide having a molecular weight of 41,000. When this polypeptide was separated with reverse-phase HPLC using a C4 column (Develosil 300C4-HG-5), a single peak was detected, confirming that the recovered aurone synthase is pure.

This polypeptide was digested by lysylendopeptidase AP1. The buffer for the reaction was 40 mM Tris-HCl (pH 9.5) containing 0.01% Tween 20 and 2 M urea. The digestion product was purified with reverse-phase HPLC using a Bakerbond ODS (4.6 mm x 25 cm) column. Namely, an aqueous solution of 0.05% trifluoroacetic acid was

used as solution A, and 80% acetonitrile containing 0.05% trifluoroacetic acid was used as solution B, and a linear concentration gradient to 90% solution A and 10% solution B was applied for first 5 minutes, and then to 100% solution B for next 80 minutes to separate the peptides.

5

The sequences of the purified peptides were determined with a peptide sequencer using a vapor phase method. The determined sequences are shown below.

P5: (K)KLGYYVYQDVEIP (SEQ ID No. 3)

10 P8: (K)IVYRQMVSAAK (SEQ ID No. 4)

P11: (K)TPQLFFGRPYRRGDQEF (SEQ ID No. 5)

P4-5: (K)IIDFELXPXPSTTMRVRAAHLVDDAYIXK (SEQ ID No.

6)

15 Example 8. Construction of cDNA Library of
Snapdragon Petals

A cDNA library from snapdragon petals was constructed according to the method described below. RNA was obtained from 5 g of fresh petals collected immediately before blooming from yellow snapdragons by using guanidine thiocyanate/cesium chloride as described in detail in Methods in Molecular Biology, Vol. 2 (Humana Press Inc., 1984) of R. McGookin, et al., followed by purification of PolyA+RNA using Oligodex dT30 (Roche Japan). A cDNA library was then prepared with this PolyA+RNA and λZAPII (Stratagene) as a vector, by using a cDNA synthesis kit and Uni-XR vector kit (Stratagene), as recommended by Stratagene. The resulting library was composed of 1.6×10^5 plaque-forming units (pfu).

25 Example 9. Acquisition of Gene Expressed in Yellow
Snapdragons by Subtraction

30 Subtraction is one of a method for acquiring a gene specifically expressed in a certain tissue at a certain time, and here was carried out using the PCR-Select™ cDNA Subtraction Kit (Clontech) as recommended. cDNA derived from yellow snapdragon petals was used as a tester, while mRNA derived from pink snapdragon petals

2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 2999

was used as a driver. DNA fragments ultimately amplified by PCR were subcloned to PCRII™ vector using a TA cloning kit (Invitrogen), followed by determination of their respective nucleotide sequences.

5 Among these, the amino acid sequence expected to be encoded by a gene named SYP8 is shown in Sequence ID No. 7.

10 RQMVSSAKTPQLFFGRPYRRGDQEFPGVGSIELVPHGMIHLWTGSENTPYGENMGAFY
STARDPIFFAHHSNVDRMWSIWKTLLGGPRRTDLTDPDFLDASFVFCDENAEMLVRVKVRDC
15 LDGKKLG (SEQ ID No. 7)

15 Within this amino acid sequence, the sequence consisting of 25 amino acids from the N-terminal and the sequence consisting of 4 amino acids from the C-terminal coincided with sequences P5, P8 and P11 obtained in Example 7. Namely, this gene fragment was found to encode aurone synthase.

Example 10. Acquisition of Full-Length Aurone
Synthase Gene

20 The previously described snapdragon cDNA library was screened by using the DNA fragment SYP8. Screening of the library was performed by using a non-radioactive system DNA detection kit (Boehringer). As a result of screening approximately 200,000 plaques, a large number of positive signals were obtained. 20 of these plaques were randomly selected, pure plaques were isolated by secondary screening, and the nucleotide sequence of the longest clone among these, SYP8-17, was determined.

25 The nucleotide sequence was determined with a synthesized oligonucleotide primer by using a DNA Sequencer Model 373A (ABI). This nucleotide sequence and its deduced amino acid sequence are shown in SEQ ID No. 1. When a database search was performed for this amino acid sequence, this gene demonstrated low homology with polyphenoloxidase gene (GenBank Association No. L29451, D45385, Z11702), and it was found to be a novel gene. 35 Furthermore, the main region having homology with

polyphenoloxidase was a copper-binding region which is the active center of polyphenoloxidase.

Example 11. Expression Manner of Aurone Synthase Gene

5 Organs and petals of yellow snapdragon at each stage of developments were used for Northern analysis by using SYP8-17 as a probe. In addition, Northern analysis was also performed by using the petals of yellow, pink and white snapdragons. The method was according to Molecular 10 Cloning (Sambrook, et al., Cold Spring Harbour Laboratory Press, 1989). The results are shown in Figs. 3, 4 and 5. Aurone synthase gene was specially expressed in petals, and moreover the expression in petals occurs parallel to biosynthesis of aurones. In addition, in the pink and 15 white petals of snapdragons in which the accumulation of mRNA of aurone synthase gene was either low or not observed at all, aurone synthesis activity was extremely weak or not detected as compared with that in the yellow petals of snapdragons. These results suggest that the 20 resulting gene is involved in aurone synthesis.

Example 12. Preparation of Verbena cDNA Library

mRNA was purified in the manner previously described from 5 g of fresh flower buds of Verbena variety Hanatemari Violet (Suntory), followed by preparation of a 25 cDNA library, as described in Example 8. A resulting library was composed of 0.8×10^6 plaque-forming units (pfu).

Example 13. Cloning of Verbena Chalcone Isomerase CDNA

30 The following primers were synthesized based on the amino acid sequences, Phe-Val/Ile-Lys-Phe-Thr-Ala-Ile (SEQ ID NO.8), Lys-Trp-Lys-Gly-Lys-Thr/Pro (SEQ ID NO.9) and a reverse sequence of a amino acid sequence, His-Ala-Val-Cys-Asn-Glu (SEQ ID NO.10), these amino acid 35 sequences are well conserved sequences compared with the known amino acid sequences of chalcone isomerase derived from higher plants.

CHI-F1: 5'-TT(T,C) (A,G)TN AA(A,G) TT(T,C) ACN GCN
AT-3' (SEQ ID NO. 11)

CHI-F2: 5'-AA(A,G) TGG AA(A,G) GGN AA(A,G) (A,C)C-3'
(SEQ ID NO. 12)

5 CHI-R2: 5'-(A,G)TG NGC NAC (A,G)CA (A,G)TT (T,C)TC-
3' (SEQ ID NO. 13)

10 Using a combination of primers of previously synthesized CHI-F1 and CHI-R2, or CHI-F2 and CHI-R2, after reacting for 2 minutes at 96°C, the reaction was repeated 30 times for 1 minute at 96°C, 1.5 minutes at 42°C and 3 minutes at 72°C, and finally reacted for 7 minutes at 72°C. When PCR was performed again under the same conditions using the resulting PCR product as a template, an approximately 200 bp PCR product was

15 amplified for the combination of CHI-F1 and CHI-R2 primers, while approximately 800, 600, 400 and 150 bp PCR products were amplified with the combination of CHI-F2 and CHI-R2 primers.

20 The resulting PCR products were subcloned to PCRII™ vector using a TA cloning kit (Invitrogen). The nucleotide sequences of the subcloned DNA fragments were determined by using the DNA Sequencer Model 373A (ABI). The PCR products obtained with each combination of primers CHI-F1 and CHI-R2, or primers CHI-F2 and CHI-R2, each had a common sequence with different lengths of 222 bp and 159 bp. The deduced amino acid sequences of these products exhibited a high degree of homology with chalcone isomerase derived from other higher plants.

25 PCR was performed by using CHI-F1 and CHI-R2 primers and an approximately 230 bp fragment obtained by digesting PCRII™ vector containing 222 bp Hanatemari chalcone isomerase as a template. After reacting for 2 minutes at 95°C by PCR using the amplified PCR product of approximately 230 bp as a template, the reaction was repeated 25 times for 1 minute at 95°C, for 1 minute at 42°C and for 4 minutes at 72°C, and finally reacting for

7 minutes at 72°C, after which it was labeled with digoxigenin and used as a probe for screening. Screening from the Hanatemari cDNA library was carried out by the recommended method with a non-radioactive system DNA detection kit (Boehringer).

5

The chalcone isomerase genes of other plants can also be obtained by using a similar method.

Example 14. Preparation of SYP8 Antigen

10 SYP8 gene described in Example 9 was expressed in E. coli using the QIA Expressionist Kit (QIAGEN) and an expression product was purified. Since the molecular weight of the purified preparation of aurone synthase is 40 to 43 kDa, the peptides of the N-terminal and C-terminal were predicted to be truncated in the mature 15 protein.

15 Therefore, QESYP8-5' and QESYP8-3' primers were synthesized so as to express the region from the 61st glycine residue to the 416th lysine residue of the amino acid sequence shown in SEQ ID NO. 2.

20 QESPY8-5': 5'-AA GAA TCC GGC CCT ATC GCC-3' (SEQ ID NO. 14)

QESPY8-3': 5'-GGG TTC GAA GAA TTC ATC TCT G-3' (SEQ ID NO. 15)

25 A BamHI site was introduced into the QESYP8-5' primer, and a HindIII site was introduced into the QESYP8-3' primer. A PCR reaction was carried out using a reaction mixture of a total of 100 µl comprising 30 pmol each of the synthesized QESYP8-5' and QESYP8-3' primers, 1 ng of SYP8-17 gene, 1 x cloned pfu DNA polymerase 30 buffer (Stratagene), 200 µM dNTPs and 5 units of cloned pfu DNA polymerase (Stratagene). After holding at 94°C for 45 seconds, the reaction was carried out for 25 cycles consisting of 45 seconds at 94°C, 45 seconds at 50°C and 4 minutes at 72°C, after which the reaction was 35 finally held at 72°C for 10 minutes. The resulting PCR product was subcloned to pCR2.1·TOPO™ vector by using a

TA cloning kit (Invitrogen) to obtain plasmid pCR·QESYP8. pCR·QESYP8 was treated with BamHI and HindIII, and a resulting DNA fragment of approximately 1 kb was ligated to a pQE30 vector (QIAGEN) which had been similarly treated with BamHI and HindIII so as to construct plasmid pQESYP8. pQESYP8 was transformed into E. coli M15 [pRep4]. Expression of SYP8 protein in E. coli and its purification were performed according to the method recommended by the manufacturers. Since the resulting purified protein was observed to have a small amount of impurity protein according to SDS-PAGE analysis, it was further purified as described below. Protein solution was concentrated to approximately 1 ml using Centriprep 10 (Amicon), dialyzed with water and freeze-dried. After treating with SDS, the impurity protein was separated using Biophoresis (Atoh, 4.5% concentration gel, 10% separation gel, 15 mA, 0.8 ml fractions). Simultaneously with concentration using Ultra-Free 10 (Millipore), the final purified preparation was transferred to PBS buffer (prepared by dissolving 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na₂HPO₄ and 0.24 g of KH₂PO₄ in 1 liter and adjusting the pH to 7.4 with hydrochloric acid) containing 0.1% CHAPS. The protein concentration in the finally purified preparation was 1.0 mg/ml.

Example 15. Preparation of SYP8 Antibody Column

Two rabbits were immunized four times with 0.2 mg each of SYP8 antigen (1.0 mg/ml) prepared in Example 14. The initial immunization was performed using Freund's complete adjuvant. Additional immunizations were performed using Freund's incomplete adjuvant. The additional immunizations were performed on days 14, 42 and 56 after the initial immunization. The method was in accordance with Vol. 12 of the Shin Seikagaku Jikken Koza. Blood samples were collected on days 52, 66 and 70 after the initial immunization, and after holding the resulting blood for 30 minutes at 37°C, it was allowed to stand undisturbed overnight at 4°C. The clot was removed

to obtain antiserum. After diluting the antiserum two-fold with 0.85% NaCl, one half volume of chilled Freegen (Hoechst Japan) was added and after stirring vigorously, the mixture was centrifuged for 5 minutes at 1500 rpm to 5 remove fat, after which the resulting supernatant was used as antiserum.

The defatted anti-SYP8 antiserum (approx. 45 ml) was 10 diluted with an equal volume of 0.15 M NaCl solution, followed by the addition of ammonium sulfate to 33% saturation and centrifuging for 30 minutes at 8000 rpm. The precipitate was dialyzed with buffer A (0.05M Tris-HCl, pH 8.6, 0.15 M NaCl). The dialysate was applied to 15 the Hi Trap Protein A column (1 ml) to purify an IgG fraction. Namely, the dialyzed sample was applied onto the Hi Trap Protein A column equilibrated with buffer A, and after washing the column with buffer A, the dialyzed sample was sequentially eluted using buffer B (0.05 M citrate buffer, pH 5.3, 0.15 M NaCl), buffer C (0.05 M acetate buffer, pH 4.3, 0.15 M NaCl) and buffer D (0.05 M 20 glycine buffer, pH 2.3, 0.15 M NaCl). IgG was confirmed to be present in both the buffer C and buffer D fractions according to ultraviolet absorption and immunodot blotting, and these fractions were mixed to form an IgG fraction. The amount of protein of the fraction was 25 approximately 70 mg. The resulting IgG fraction was dialyzed with 0.1 M NaHCO₃ and 0.5 M NaCl, after which it was concentrated to approximately 2 mg/ml with Centricon 10 (Amicon).

30 4.5 g of CNBr-activated Sepharose 4B was suspended in 45 ml of 1 mM HCl and washed with 500 ml of 1 mM HCl over a Buchner funnel. The washed resin was added a little at a time to the concentrated IgG solution and suspended, and shaken overnight at 4°C to immobilize the IgG. The resin was collected by filtration with 35 aspiration over a Buchner funnel, resuspended in 30 ml of 0.2 M Tris-HCl buffer (pH 8.5), and the suspension was shaken for two nights at 4°C so as to inactivate residual

active groups on the resin. Next, the resin was sequentially washed with 0.2 M acetate buffer (pH 5.0), Tris-HCl buffer (pH 8.5), 0.01 M potassium phosphate buffer (pH 7.8) and 0.2 M NaCl. As a control, anti-band 5 IgG and anti- β -galactosidase IgG were respectively immobilized to Sepharose 4B in the same manner. This Sepharose 4B was used as IgG-Sepharose 4B suspension (anti-SYP8, anti-band A, anti- β -galactosidase) in Example 16. Furthermore, the weight of reacted IgG per unit 10 resin weight was set to be roughly the same for all three types. The immobilization yield was 90 to 100%.

Example 16. Immunoprecipitation Experiment

0, 200, 500 and 815 μ l each of aqueous bovine serum albumin solution (final concentration 0.1%) and IgG-Sepharose 4B suspension prepared in Example 15 (anti-SYP8, anti-band A, anti- β -galactosidase; resin 15 phase:liquid phase = 2:1 v/v) were added to a amount of enzyme solution, and then the mixture was brought to a final volume of 1 ml with 0.01 M potassium phosphate buffer (pH 7.8) and 0.2 M NaCl. After shaking the 20 mixture for 24 hours at 4°C and centrifuging for 20 minutes at 13,000 rpm, aurone synthase activity of the supernatant was measured.

Namely, aurone synthase activity was measured by 25 adding CHAPS having a final concentration of 0.1%, 5 mM H_2O_2 and 0.1 M citrate buffer to the supernatant to make the pH 5.4, bringing the total volume to 395 μ l and holding for 15 minutes at 30°C, followed by addition of 5 μ l of THC (dissolved with ethanol so that A366 = 600) to 30 start the reaction. After allowing to react for 60 minutes at 30°C, 100 μ l of 10% TFA and 90% acetonitrile were added to stop the reaction. Activity was then measured by analyzing the reaction mixture by HPLC as described in Example 3.

35 As shown in Fig. 6, when anti-SYP8-IgG-Sepharose 4B

was used, enzyme activity in the supernatant decreased dependent on the amount of anti-SYP8-IgG-Sepharose 4B added. There was no change in aurone synthase activity in the case of adding anti-band A-IgG-Sepharose 4B or 5 anti- β -galactosidase-IgG-Sepharose 4B as a control. In addition, the resin collected as precipitate was washed with 0.01 M potassium phosphate buffer and 0.2 M NaCl, followed by measurement of aurone synthase activity. As a result, aurone synthase activity was observed only for 10 anti-SYP8-IgG-Sepharose 4B.

When the supernatant was analyzed by SDS-PAGE and Western blotting, the signal of aurone synthase decreased dependent on the amount of anti-SYP8-IgG-Sepharose 4B as shown in Fig. 7. On the other hand, in a similar 15 experiment using anti-band A-IgG-Sepharose 4B as control, the signal of the aurone synthase gene was constant regardless of the amount of anti-band A-IgG-Sepharose 4B added.

According to these results, SYP8 gene was confirmed 20 to encode aurone synthase. Note that an approximately 80 kDa signal was detected dependent on the amount of anti-SYP8-IgG-Sepharose 4B added in Fig. 7. Since this signal increases with storage time of the resin until the 25 experiment, this signal is thought to have been derived from IgG liberated from the Sepharose 4B resin.

Example 17.

As was described in Example 10, aurone synthase demonstrates weak homology with polyphenol oxidase at the 30 amino acid level, and the major region possessing that homology is the region that binds to copper. Accordingly, since it is expected that aurone synthase is also a copper enzyme, atomic absorption analysis was performed on aureusidin synthase. The Shimazu AA-6700F was used for the measurement system, and measurement was 35 performed in the furnace measurement mode at a wavelength of 324.8 nm.

A calibration curve (calibration range: 0 to 9 ppb)

was prepared using a 1000 ppm copper standard solution (Wako Pure Chemical Industries) diluted 1000-fold with concentrated sulfuric acid. Since other organic substances present may obstruct measurement in the case of analysis by atomic absorption analysis, measurement of the atomic absorption of copper was confirmed to be possible even in acetic acid buffer containing 0.1% CHAPS in advance by using mushroom tyrosinase (enzyme containing copper ion) prior to measurement. Next, pure aureusidin synthase (200 μ l) was thoroughly dialyzed against acetic acid buffer (pH 6.0) containing 0.1% CHAPS. Known amounts of several standard proteins were analyzed by SDS-PAGE, the darkness of the resulting silver-colored bands was quantified with an image scanner, and a calibration curve was prepared for determining the amount of protein from band darkness. A portion of the pure aureusidin synthase was applied to SDS-PAGE under the same conditions, its silver-colored band was quantified with an image scanner, and protein concentration was calculated from the previously prepared calibration curve. Copper was detected by adding 0.5 μ l of concentrated sulfuric acid (1.38 N) to 100 μ l of pure aureusidin synthase and measuring. Accordingly, this enzyme was clearly shown to be a copper enzyme.

Example 18. Aurone Synthesis Activity of Tyrosinase
After mixing tyrosinase (Sigma catalog no. T7755; 0.04 mg/ml, 10 μ l), 0.1 M sodium phosphate buffer (pH 6.5, 335 μ l), 9% CHAPS (20 μ l) and milli-Q water (20 μ l), the mixture was incubated for 10 minutes at 30°C, followed by the addition of tetrahydroxychalcone (THC, 4.3 mM in ethanol, 15 μ l), stirring immediately and reacting for 30 minutes at 30°C. After reaction, 100 μ l of reaction stopping solution (10% trifluoroacetate solution containing 90% acetonitrile) was added to the reaction mixture to stop the reaction, followed by HPLC

analysis. Analysis was performed in the same manner as described in Example 3. Water was used instead of tyrosinase as a control.

5 In the case of addition of tyrosinase, the substrate THC was eluted in approximately 15.9 minutes, while the reaction product aureusidin was eluted in approximately 12.5 minutes. On the other hand, in the case of addition of water instead of tyrosinase, the substrate THC was eluted in approximately 16 minutes, while aureusidin was 10 not eluted.

15 In addition, the reaction was carried out under the same conditions using pentahydroxychalcone (PHC) instead of THC as a substrate, and using 0.116 M sodium citrate phosphate buffer (pH 5.4) as a buffer. Similarly, water was used instead of tyrosinase as a control.

20 In the case of addition of tyrosinase, the substrate PHC was eluted in approximately 14.7 minutes, while the reaction product aureusidin was eluted in approximately 12.5 minutes. On the other hand, in the case of adding water instead of tyrosinase, although the substrate PHC was eluted in approximately 14.6 minutes, aureusidin was not eluted.

25 Thus, tyrosinase was clearly shown to also have activity to synthesize aurone.

Industrial Applicability

As has been described above, according to the present invention, a reaction in which aureusidin, a kind of aurone, is synthesized from tetrahydroxychalcone was 30 observed for the first time, aureusidin synthase that catalyzes this reaction was isolated and purified, its amino acid sequence was determined, and its gene was cloned. Here, although snapdragon was used for the enzyme source, enzymes that synthesize aurones can be 35 purified from other plants containing aurones using a similar method, and their genes can be obtained.

Alternatively, since genes encoding enzymes that

catalyze the same reaction are known to have mutually homologous nucleotide sequences and hybridize, a gene encoding an enzyme that synthesizes aurones can be obtained from another source based on the cDNA obtained 5 from snapdragon.

In addition, a gene that encodes protein having activity to synthesize aurones by using chalcones as substrates can also be obtained from polyphenol oxidase.

The introduction of a target gene into a plant is 10 currently widely known, and the present invention makes it possible to breed yellow flowers from plant species that do not inherently possess yellow flowers. Moreover, it is also possible to change the color tone in plant species having yellow flowers.

CLAIMS

1. A gene encoding a protein having activity to synthesize aurones by using chalcones as substrates.

5 2. A gene as set forth in claim 1 wherein said protein is a polyphenol oxidase.

10 3. A gene as set forth in claim 1 or 2, encoding a protein having the amino acid sequence described in SEQ ID No. 2 or an amino acid sequence modified by deletion, substitution and/or addition of one or more amino acids relative to that amino acid sequence, and having activity to synthesize aurones by using chalcones as substrates.

15 4. A gene as set forth in claim 1 or 2, capable of hybridizing under stringent conditions with a nucleic acid having the nucleotide sequence described in Sequence ID No. 1, and encoding a protein having activity to synthesize aurones by using chalcones as substrates.

20 5. A gene as set forth in claim 1 or 2 having sequence homology of at least 55% relative to the amino acid sequence described in SEQ ID No. 2, and encoding a protein having activity to synthesize aurones by using chalcones as substrates.

6. A vector comprising a gene as set forth in any one of claims 1 through 5.

25 7. A host transformed by a vector as set forth in claim 6.

8. A host as set forth in claim 7 wherein said host is a microorganism or animal cell.

9. A host as set forth in claim 7 wherein said host is a plant cell or plant.

30 10. A protein encoded by a gene as set forth in any one of claims 1 through 5.

35 11. A protein able to specifically bind with antibody to the protein as set forth in claim 10, and having activity to synthesize aurones by using chalcones as substrates.

12. A process for production of said protein characterized by culturing or growing a host as set forth

in claim 7, and harvesting or purifying from said host a protein having activity to synthesize aurones by using chalcones as substrates.

5 13. A process for harvesting or purifying a protein having activity to synthesize aurones by using chalcones as substrates, characterized by utilizing specific binding with antibody to the protein as set forth in claim 10 or claim 11.

10 14. A process for synthesizing aurone characterized in that a protein as set forth in claim 10 or claim 11 is allowed to act on chalcones.

15 15. A process for synthesizing aurones in a plant characterized by transforming a plant or plant cells with a gene as set forth in any one of claims 1 through 5, expressing said gene, and using the formed protein to synthesize aurones within a plant.

20 16. A plant in which flower color is regulated by introducing a gene as set forth in any one of claims 1 through 5, or its progeny or tissue having the same properties.

17. A plant as set forth in claim 16 in which flower color is regulated to yellow, or its progeny or tissue having the same properties.

ABSTRACT

The present invention provides a protein having aurone synthase activity involved in the color of flowers such as snapdragons, a gene that encodes it, cDNA in particular, and its applications. This gene can give yellow color to the flowers of plants by introducing into plants deficient in chalcone isomerase and so forth and expressing.

Fig. 1





Fig. 2



09/446089

Fig. 3

Leaf
Stem
Bud
Petal

↔ 3.4kb

↔ 1.8kb

Fig. 4

petal stage

1 2 3 4 5 6



3/6

09/446089


Fig. 5

yellow
pink
white

↔ 3.4 kb

↔ 1.8 kb


Fig. 6



09/446089

Fig. 7

Amount of anti-SYP8-Sepharose 4B
added



6/6

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

GENE ENCODING A PROTEIN HAVING

AURONE SYNTHESIS ACTIVITY

上記発明の明細書（下記の欄でxがついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

一月一日に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
 (該当する場合) _____ に訂正されました。

was filed on April 16, 1999
 as United States Application Number or
 PCT International Application Number
PCT/JP99/02045 and was amended on
 _____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration
(日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

10-107296(Pat. Appln.) Japan
(Number) (Country)
(番号) (国名)

(Number) (Country)
(番号) (国名)

私は、第35編米国法典119条(e)項に基いて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基いて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願者提出日以降で本出願の日本国内または特許協力条約国提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

優先権主張なし

17/April/1998

(Day/Month/Year Filed)
(出願年月日)

(Day/Month/Year Filed)
(出願年月日)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

委任状： 私は下記の発明者として、本出願に関する一切の手続を米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。（弁護士、または代理人の氏名及び登録番号を明記のこと）

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

William L. Mathis	17,337	Robert G. Mukai	28,531	William H. Benz	25,952
Peter H. Smolka	15,913	George A. Hovanec, Jr.	28,223	Peter K. Skiff	31,917
Robert S. Swecker	19,885	James A. LaBarre	28,632	Richard J. McGrath	29,195
Platon N. Mandros	22,124	E. Joseph Gess	28,510	Matthew L. Schneider	32,814
Benton S. Duffett, Jr.	22,030	R. Danny Huntington	27,903	Michael G. Savage	32,596
Joseph R. Magnone	24,239	Eric H. Weisblatt	30,505	Gerald F. Swiss	30,113
Norman H. Stepno	22,716	James W. Peterson	26,057	Michael J. Ure	33,089
Ronald L. Grudziecki	24,970	Teresa Stanek Rea	30,422	Charles F. Wieland III	33,096
Frederick G. Michaud, Jr.	26,003	Robert E. Krebs	25,885	Bruce T. Wieder	33,815
Alan E. Kopecki	25,813	William C. Rowland	30,888	Todd R. Walters	34,040
Regis E. Slutter	26,999	T. Gene Dillahunt	25,423		
Samuel C. Miller, III	27,360	Patrick C. Keane	32,858		
Ralph L. Freeland, Jr.	16,410	Bruce J. Boggs, Jr.	32,344		

書類送付先

Send Correspondence to:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

直接電話連絡先：（名前及び電話番号）

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki
at (703) 836-6620

唯一または第一発明者名	1-00	Full name of sole or first inventor	Keiko Sakakibara
発明者の署名	日付	Inventor's signature	木下原 真子
住所		Residence	Dec. 2, 1999
		Muko-shi, Kyoto, Japan	JPX
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	3-1-327, Nishitanakase, Terado-cho,
			Muko-shi, Kyoto 617-0002, Japan
第二共同発明者	2-00	Full name of second joint inventor, if any	Yuko Fukui
第二共同発明者	日付	Second inventor's signature	福井 祐子
住所		Date	Dec. 2, 1999
		Mishima-gun, Osaka, Japan	JPX
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	2-8-2-907, Minase, Shimamoto-cho,
			Mishima-gun, Osaka 618-0014, Japan

(第三以降の共同発明者についても同様に記載し、署名をすること)
(Supply similar information and signature for third and subsequent joint inventors.)

YFi (cont'd)
see paper
No. 6
M

第三共同発明者	3-00	Full name of third joint inventor, if any <u>Yoshikazu Tanaka</u>
第三共同発明者	日付	Third inventor's signature <u>田中 良和</u> Date Dec. 2, 1999
住所		Residence <u>Otsu-shi, Shiga, Japan</u> JPY
国籍		Citizenship Japanese
私書箱		Post Office Address 2-7-4, Oginosato, Otsu-shi, Shiga 520-0246, Japan
第四共同発明者	4-00	Full name of fourth joint inventor, if any <u>Takaaki Kusumi</u>
第四共同発明者	日付	Fourth inventor's signature <u>久住高志</u> Date Dec. 2, 1999
住所		Residence <u>Suita-shi, Osaka, Japan</u> JPY
国籍		Citizenship Japanese
私書箱		Post Office Address 2-12-21-402, Yamate-cho, Suita-shi, Osaka 564-0073, Japan
第五共同発明者	5-00	Full name of fifth joint inventor, if any <u>Masako Mizutani</u>
第五共同発明者	日付	Fifth inventor's signature <u>水谷正子</u> Date Dec. 2, 1999
住所		Residence <u>Kyoto-shi, Kyoto, Japan</u> JPY
国籍		Citizenship Japanese
私書箱		Post Office Address 53-60, Katsurainui-cho, Nishikyo-ku, Kyoto-shi, Kyoto 615-8086, Japan
第六共同発明者	6-00	Full name of sixth joint inventor, if any <u>Toru Nakayama</u>
第六共同発明者	日付	Sixth inventor's signature <u>中山 透</u> Date Dec. 2, 1999
住所		Residence <u>Sendai-shi, Miyagi, Japan</u> JPY
国籍		Citizenship Japanese
私書箱		Post Office Address 2-1-305, Kitatakamori, Izumi-ku, Sendai-shi, Miyagi 981-3202, Japan

(第七以降の共同発明者についても同様に
記載し、署名をすること)

(Supply similar information and signature for
seventh and subsequent joint inventors.)

09/446089

420 Rec'd PCT/PTO 17 DEC 1999

SEQUENCE LISTING

<110> SUNTORY LIMITED

<120> Gene encoding a protein having aurone synthesis activity

<130> G837

<150> JP 10-107296

<151> 1998-04-17

<160> 15

<210> 1

<211> 1951

<212> DNA

<213> *Antirrhinum majus*

<220>

<221> CDS

<222> (96)...(1781)

<223> Nucleotide sequence encoding a protein having aurone synthesis activity

<400> 1

aaattacatt gcttccttg tcccaccttc caccaccaat atatacaact tcctcagcta 60

gttgtttatt atcaatcaaa taaaattatt tccca atg ttc aaa aat cct aat 113

Met Phe Lys Asn Pro Asn

1 5

atc cgc tat cac aaa cta tct tcc aaa tcc aat gac aac gat caa gaa 161

Ile Arg Tyr His Lys Leu Ser Ser Lys Ser Asn Asp Asn Asp Gln Glu

10 15 20

tcc tcc cat cgt tgt aag cac att cta tta ttt ata ata acc tta ttc 209

Ser Ser His Arg Cys Lys His Ile Leu Leu Phe Ile Ile Thr Leu Phe

25 30 35

cta ctt ata gtt ggc ctg tac atc gcc aac tct ctc gcc tat gcc cgg	257		
Leu Leu Ile Val Gly Leu Tyr Ile Ala Asn Ser Leu Ala Tyr Ala Arg			
40	45	50	
ttt gcc tcg acc tca acc ggc cct atc gcc gcc cct gat gtc acc aaa	305		
Phe Ala Ser Thr Ser Thr Gly Pro Ile Ala Ala Pro Asp Val Thr Lys			
55	60	65	70
tgt ggt cag cca gac ttg cca cct ggc aca gcc cca ata aac tgt tgt	353		
Cys Gly Gln Pro Asp Leu Pro Pro Gly Thr Ala Pro Ile Asn Cys Cys			
75	80	85	
ccc cca atc ccc gct aaa atc atc gat ttc gag cta cca cct ccc tcc	401		
Pro Pro Ile Pro Ala Lys Ile Ile Asp Phe Glu Leu Pro Pro Pro Ser			
90	95	100	
act acc atg agg gtt cgc cgt gcg gct cat tta gtt gat gat gca tac	449		
Thr Thr Met Arg Val Arg Arg Ala Ala His Leu Val Asp Asp Ala Tyr			
105	110	115	
att gcc aaa ttc aag aaa gcc gtt gag ctt atg cga gct cta cct gag	497		
Ile Ala Lys Phe Lys Lys Ala Val Glu Leu Met Arg Ala Leu Pro Glu			
120	125	130	
gat gac cct cgt agc ttc aag caa caa gct aac gtc cat tgc gct tac	545		
Asp Asp Pro Arg Ser Phe Lys Gln Gln Ala Asn Val His Cys Ala Tyr			
135	140	145	150
tgc gcg ggg gcg tat aat caa gcc ggt ttc aca aac cta aag ctc caa	593		
Cys Ala Gly Ala Tyr Asn Gln Ala Gly Phe Thr Asn Leu Lys Leu Gln			
155	160	165	
atc cac cga tct tgg ctt ttt ttc ccg ttc cat aga tat tat atc tac	641		
Ile His Arg Ser Trp Leu Phe Phe Pro Phe His Arg Tyr Tyr Ile Tyr			
170	175	180	
ttt ttt gaa aga ata ttg gga aaa cta atc aat gat aca act ttt gct	689		
Phe Phe Glu Arg Ile Leu Gly Lys Leu Ile Asn Asp Thr Thr Phe Ala			
185	190	195	
ctc cca ttt tgg aac tat gat tca cct ggt gga atg aca atc cca tca	737		
Leu Pro Phe Trp Asn Tyr Asp Ser Pro Gly Gly Met Thr Ile Pro Ser			
200	205	210	
atg ttt att gat act aat tct tcg ctg tac gat agt tta cgg gac agt	785		
Met Phe Ile Asp Thr Asn Ser Ser Leu Tyr Asp Ser Leu Arg Asp Ser			
215	220	225	230
aat cat cag cca cca acc atc gta gac ttg aac tac gcc ttt tct gat	833		
Asn His Gln Pro Pro Thr Ile Val Asp Leu Asn Tyr Ala Phe Ser Asp			
235	240	245	

tcc gac aat acc act act cct gaa gag caa atg att ata aac ctt aaa			881
Ser Asp Asn Thr Thr Pro Glu Glu Gln Met Ile Ile Asn Leu Lys			
250	255	260	
att gtg tac aga caa atg gtg tcg agc gct aag act cca cag ctt ttc			929
Ile Val Tyr Arg Gln Met Val Ser Ser Ala Lys Thr Pro Gln Leu Phe			
265	270	275	
ttc ggc cgc cca tac cga cgt ggg gac caa gag ttt ccc ggg gtg ggg			977
Phe Gly Arg Pro Tyr Arg Arg Gly Asp Gln Glu Phe Pro Gly Val Gly			
280	285	290	
tcg att gag tta gtc cct cat ggc atg ata cat tta tgg acc ggt tct			1025
Ser Ile Glu Leu Val Pro His Gly Met Ile His Leu Trp Thr Gly Ser			
295	300	305	310
gag aac acg ccc tat ggc gag aac atg ggg gct ttc tac tca acg gct			1073
Glu Asn Thr Pro Tyr Gly Glu Asn Met Gly Ala Phe Tyr Ser Thr Ala			
315	320	325	
aga gac ccg ata ttt ttt gct cat cat tcg aac gtc gat aga atg tgg			1121
Arg Asp Pro Ile Phe Phe Ala His His Ser Asn Val Asp Arg Met Trp			
330	335	340	
tcc ata tgg aag acc cta gga ggg ccg cgg agg acg gac tta aca gat			1169
Ser Ile Trp Lys Thr Leu Gly Gly Pro Arg Arg Thr Asp Leu Thr Asp			
345	350	355	
cca gat ttt ctt gat gcg tct ttc gtt ttt tat gac gaa aac gca gag			1217
Pro Asp Phe Leu Asp Ala Ser Phe Val Phe Tyr Asp Glu Asn Ala Glu			
360	365	370	
atg gtt cgg gtc aag gtt cgg gat tgc tta gat gaa aag aaa cta ggg			1265
Met Val Arg Val Lys Val Arg Asp Cys Leu Asp Glu Lys Lys Leu Gly			
375	380	385	390
tac gtt tat caa gat gtg gag att ccg tgg ctc aac act cgt cca aca			1313
Tyr Val Tyr Gln Asp Val Glu Ile Pro Trp Leu Asn Thr Arg Pro Thr			
395	400	405	
cca aaa gtt tct ccg tct cta ctt aag aaa ttt cat aga aca aac act			1361
Pro Lys Val Ser Pro Ser Leu Leu Lys Lys Phe His Arg Thr Asn Thr			
410	415	420	
gcc aat ccg aga caa gtt ttt cct gcg ata ctt gac aga gtc tta aaa			1409
Ala Asn Pro Arg Gln Val Phe Pro Ala Ile Leu Asp Arg Val Leu Lys			
425	430	435	
gtt atc gtg acg agg ccg aag aaa act aga agt agg aaa gaa aag gac			1457
Val Ile Val Thr Arg Pro Lys Lys Thr Arg Ser Arg Lys Glu Lys Asp			
440	445	450	

gag tta gaa gag att tta gtg att gaa ggg att gaa ctg gaa aga gac	1505		
Glu Leu Glu Glu Ile Leu Val Ile Glu Gly Ile Glu Leu Glu Arg Asp			
455	460	465	470
cac ggg cac gta aaa ttc gac gtt tat att aat gct gac gaa gat gac	1553		
His Gly His Val Lys Phe Asp Val Tyr Ile Asn Ala Asp Glu Asp Asp			
475	480	485	
ctt gcg gtg att tcg ccg gag aat gct gag ttc gcc ggg agt ttc gtg	1601		
Leu Ala Val Ile Ser Pro Glu Asn Ala Glu Phe Ala Gly Ser Phe Val			
490	495	500	
agt ctg tgg cac aaa cct ata aag ggg aag agg aca aag acg cag tta	1649		
Ser Leu Trp His Lys Pro Ile Lys Gly Lys Arg Thr Lys Thr Gln Leu			
505	510	515	
tta aca ttg tcg att tgt gat att ttg gag gat ttg gat gct gac gaa	1697		
Leu Thr Leu Ser Ile Cys Asp Ile Leu Glu Asp Leu Asp Ala Asp Glu			
520	525	530	
gat gat tat gtg ttg gtc act ttg gtt ccg aga aac gcc gga gat gcg	1745		
Asp Asp Tyr Val Leu Val Thr Leu Val Pro Arg Asn Ala Gly Asp Ala			
535	540	545	550
atc aag att cat aat gtc aag att gag ctt gat ggc taataaattc	1791		
Ile Lys Ile His Asn Val Lys Ile Glu Leu Asp Gly			
555	560	562	
tattgatttc ttctcaacct acagttgatc atttaccgat tgattattcc aataaaagta	1851		
tctcatgtac caatatcgat cgtattaatc gtaatacttt cagattttta tttattnaa	1911		
agcagttgtta taaatggta aataaggatt actttttgag	1951		

<210> 2

<211> 562

<212> PRT

<213> *Antirrhinum majus*

<220>

<223> Amino acid sequence of a protein having aurone synthesis activity

<400> 2

Met Phe Lys Asn Pro Asn Ile Arg Tyr His Lys Leu Ser Ser Lys Ser			
1	5	10	15

Asn	Asp	Asn	Asp	Gln	Glu	Ser	Ser	His	Arg	Cys	Lys	His	Ile	Leu	Leu
20								25					30		
Phe	Ile	Ile	Thr	Leu	Phe	Leu	Leu	Ile	Val	Gly	Leu	Tyr	Ile	Ala	Asn
35								40					45		
Ser	Leu	Ala	Tyr	Ala	Arg	Phe	Ala	Ser	Thr	Ser	Thr	Gly	Pro	Ile	Ala
50								55				60			
Ala	Pro	Asp	Val	Thr	Lys	Cys	Gly	Gln	Pro	Asp	Leu	Pro	Pro	Gly	Thr
65								70			75		80		
Ala	Pro	Ile	Asn	Cys	Cys	Pro	Pro	Ile	Pro	Ala	Lys	Ile	Ile	Asp	Phe
85								90			95				
Glu	Leu	Pro	Pro	Pro	Ser	Thr	Thr	Met	Arg	Val	Arg	Arg	Ala	Ala	His
100								105			110				
Leu	Val	Asp	Asp	Ala	Tyr	Ile	Ala	Lys	Phe	Lys	Lys	Ala	Val	Glu	Leu
115								120			125				
Met	Arg	Ala	Leu	Pro	Glu	Asp	Asp	Pro	Arg	Ser	Phe	Lys	Gln	Gln	Ala
130								135			140				
Asn	Val	His	Cys	Ala	Tyr	Cys	Ala	Gly	Ala	Tyr	Asn	Gln	Ala	Gly	Phe
145								150			155		160		
Thr	Asn	Leu	Lys	Leu	Gln	Ile	His	Arg	Ser	Trp	Leu	Phe	Phe	Pro	Phe
165								170			175				
His	Arg	Tyr	Tyr	Ile	Tyr	Phe	Phe	Glu	Arg	Ile	Leu	Gly	Lys	Leu	Ile
180								185			190				
Asn	Asp	Thr	Thr	Phe	Ala	Leu	Pro	Phe	Trp	Asn	Tyr	Asp	Ser	Pro	Gly
195								200			205				
Gly	Met	Thr	Ile	Pro	Ser	Met	Phe	Ile	Asp	Thr	Asn	Ser	Ser	Leu	Tyr
210								215			220				
Asp	Ser	Leu	Arg	Asp	Ser	Asn	His	Gln	Pro	Pro	Thr	Ile	Val	Asp	Leu
225								230			235		240		
Asn	Tyr	Ala	Phe	Ser	Asp	Ser	Asp	Asn	Thr	Thr	Thr	Pro	Glu	Glu	Gln
245								250			255				
Met	Ile	Ile	Asn	Leu	Lys	Ile	Val	Tyr	Arg	Gln	Met	Val	Ser	Ser	Ala
260								265			270				
Lys	Thr	Pro	Gln	Leu	Phe	Phe	Gly	Arg	Pro	Tyr	Arg	Arg	Gly	Asp	Gln
275								280			285				
Glu	Phe	Pro	Gly	Val	Gly	Ser	Ile	Glu	Leu	Val	Pro	His	Gly	Met	Ile
290								295			300				
His	Leu	Trp	Thr	Gly	Ser	Glu	Asn	Thr	Pro	Tyr	Gly	Glu	Asn	Met	Gly
305								310			315		320		

Ala Phe Tyr Ser Thr Ala Arg Asp Pro Ile Phe Phe Ala His His Ser
325 330 335
Asn Val Asp Arg Met Trp Ser Ile Trp Lys Thr Leu Gly Gly Pro Arg
340 345 350
Arg Thr Asp Leu Thr Asp Pro Asp Phe Leu Asp Ala Ser Phe Val Phe
355 360 365
Tyr Asp Glu Asn Ala Glu Met Val Arg Val Lys Val Arg Asp Cys Leu
370 375 380
Asp Glu Lys Lys Leu Gly Tyr Val Tyr Gln Asp Val Glu Ile Pro Trp
385 390 395 400
Leu Asn Thr Arg Pro Thr Pro Lys Val Ser Pro Ser Leu Leu Lys Lys
405 410 415
Phe His Arg Thr Asn Thr Ala Asn Pro Arg Gln Val Phe Pro Ala Ile
420 425 430
Leu Asp Arg Val Leu Lys Val Ile Val Thr Arg Pro Lys Lys Thr Arg
435 440 445
Ser Arg Lys Glu Lys Asp Glu Leu Glu Glu Ile Leu Val Ile Glu Gly
450 455 460
Ile Glu Leu Glu Arg Asp His Gly His Val Lys Phe Asp Val Tyr Ile
465 470 475 480
Asn Ala Asp Glu Asp Asp Leu Ala Val Ile Ser Pro Glu Asn Ala Glu
485 490 495
Phe Ala Gly Ser Phe Val Ser Leu Trp His Lys Pro Ile Lys Gly Lys
500 505 510
Arg Thr Lys Thr Gln Leu Leu Thr Leu Ser Ile Cys Asp Ile Leu Glu
515 520 525
Asp Leu Asp Ala Asp Glu Asp Asp Tyr Val Leu Val Thr Leu Val Pro
530 535 540
Arg Asn Ala Gly Asp Ala Ile Lys Ile His Asn Val Lys Ile Glu Leu
545 550 555 560
Asp Gly
562

<210> 3
<211> 13
<212> PRT
<213> Antirrhinum majus

<220>

<223> Partial amino acid sequence of a protein having aurone synthesis activity

<400> 3

Lys Lys Leu Gly Tyr Val Tyr Gln Asp Val Glu Ile Pro
5 10

<210> 4

<211> 12

<212> PRT

<213> *Antirrhinum majus*

<220>

<223> Partial amino acid sequence of a protein having aurone synthesis activity

<400> 4

Lys Ile Val Tyr Arg Gln Met Val Ser Ser Ala Lys
5 10

<210> 5

<211> 18

<212> PRT

<213> *Antirrhinum majus*

<220>

<223> Partial amino acid sequence of a protein having aurone synthesis activity

<400> 5

Lys Thr Pro Gln Leu Phe Phe Gly Arg Pro Tyr Arg Arg Gly Asp Gln
5 10 15
Glu Phe

<210> 6

<211> 30

<212> PRT

Lys Thr Leu Gly Gly Pro Arg Arg Thr Asp Leu Thr Asp Pro Asp Phe
85 90 95
Leu Asp Ala Ser Phe Val Phe Cys Asp Glu Asn Ala Glu Met Val Arg
100 105 110
Val Lys Val Arg Asp Cys Leu Asp Gly Lys Lys Leu Gly
115 120 125

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221>

<222> (2)

<223> Xaa is Val or Ile

<400> 8

Phe Xaa Lys Phe Thr Ala Ile

5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221>

<222> (6)

<223> Xaa is Thr or Pro

<400> 9

Lys Trp Lys Gly Lys Xaa

5

<210> 10

<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<221>
<222>
<223>

<400> 10
His Ala Val Cys Asn Glu

5

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 11
ttyrtnaart tyacngcnat

20

<210> 12
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 12
aartggaarg gnaarmc

17

<210> 13
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 13
rtgngcnacr cartt ytc

18

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 14
aaggatccgg ccctatcgcc

20

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 15

gggttcgaag aattcatctc tg

22